Archives
-
Senescent CAFs Drive Breast Cancer Progression
2026-08-20
The reference study identifies senescent myofibroblast cancer-associated fibroblasts as an immunosuppressive stromal population that promotes breast tumor growth by limiting natural killer cell cytotoxicity through secreted extracellular matrix. Its mouse intervention data and human tumor analyses support senCAF depletion as a potential stromal strategy, while also highlighting important limits in translating association into therapy.
-
CCK-8 for Mechanistic Drug Screening in IBD
2026-08-19
Discover how CCK8 can strengthen inflammatory disease research by separating true pathway modulation from treatment-induced loss of viable cells. This guide applies Cell Counting Kit-8 to mechanistic screening inspired by TAK875 and STAT3 biology.
-
DiscoveryProbe FDA-approved Drug Library Workflow
2026-08-19
Turn a regulatory-approved compound collection into a mechanism-aware workflow for phenotypic screening, combination testing, and target discovery. This guide applies the DiscoveryProbe FDA-approved Drug Library to ChaC1–glutathione biology while providing practical controls, assay parameters, and troubleshooting strategies.
-
Astrocyte–Microglia Crosstalk in CNS Repair
2026-08-18
A 2026 Cell Reports study identifies a reciprocal CSF1–IFN-β signaling circuit between lesion-border astrocytes and microglia after spinal cord injury. The findings connect astrocyte-supported microglial proliferation with astrocyte survival, wound-border formation, and motor recovery, offering a mechanistic framework for studying glial coordination in neural repair.
-
SARS-CoV-2 Variant Shifts in ACE2 Receptor Usage
2026-08-18
Shukla et al. developed a barcoded pseudotyped-virus assay that simultaneously measures how multiple ACE2 sequences support entry by SARS-CoV-2 spike variants. The study shows that variant effects are modest for human ACE2 but can substantially reshape compatibility with animal orthologs, offering a scalable framework for studying receptor usage and potential host-range changes.
-
ECL Western Blotting Substrate: Practical Protocol
2026-08-17
ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for sensitive, nonradioactive protein detection on immunoblots. It is intended for HRP Western blot workflows using X-ray film or CCD imaging, not for fluorescent or radioisotopic detection methods.
-
Cytarabine (AraC): Cell-Death Research Workflow
2026-08-17
Build a reproducible Cytarabine workflow that connects DNA synthesis blockade, deoxycytidine kinase activation, and apoptosis readouts in leukemia models. A carefully bounded comparison with viral RIPK3 degradation research helps distinguish direct AraC effects from broader regulated-cell-death phenotypes.
-
From mRNA Uptake to Function: A Translational Roadmap
2026-08-16
Translational mRNA research increasingly depends on separating delivery, intracellular trafficking, and protein expression rather than treating transfection as a single endpoint. This article connects findings from heterogeneous blood-cell electroporation with the dual-readout strategy of EZ Cap™ Cy5 EGFP mRNA (5-moUTP), outlining a practical framework for delivery optimization, mechanistic interpretation, and translational decision-making.
-
Cyclophosphamide: From DNA Damage to Translation
2026-08-15
A translational framework for using Cyclophosphamide as both an alkylating chemotherapeutic agent and an immune-modulating research tool. The article connects hepatic bioactivation, DNA cross-linking, apoptosis induction in cancer cells, immune depletion, experimental design, and strategic comparison with topotecan.
-
Trichostatin A (TSA) Workflows for Epigenetic Research
2026-08-14
Trichostatin A (TSA) provides reversible HDAC inhibition for connecting histone acetylation with proliferation, differentiation, and senescence phenotypes. This workflow-centered guide combines cancer assays with a carefully bounded strategy for testing whether chromatin regulation intersects with the mitochondrion-processed TERC-53 pathway.
-
HDAC Inhibitors Repress NUT Function in NUT Carcinoma
2026-08-14
Shiota and colleagues developed a dCAS9-based chemical screen that identified structurally diverse HDAC inhibitors as suppressors of NUT-dependent transcription. The study links HDAC inhibition to disruption of BRD4-NUT megadomains, oncogene repression, differentiation, and enhanced tumor control when combined with bromodomain inhibition.
-
Heparin Sodium as an HSPG Assay Probe
2026-08-13
Heparin sodium is more than a coagulation reagent: it can help researchers interrogate glycan-dependent molecular interactions. This article connects anticoagulation readouts with heparan sulfate proteoglycan biology and offers a controlled framework for interpreting extracellular vesicle uptake assays.
-
ETS1, Mitophagy, and BPD: SENP2/HSPA8/FUNDC1
2026-08-13
The reference study identifies ETS1 as a transcriptional regulator that protects against hyperoxia-associated bronchopulmonary dysplasia by suppressing excessive mitochondrial damage-induced mitophagy. Its mechanistic contribution is the definition of an ETS1–SENP2–HSPA8–FUNDC1 pathway in which FUNDC1 deSUMOylation promotes chaperone-dependent degradation, linking transcriptional control with mitochondrial quality control.
-
AG-120 (Ivosidenib) in IDH1-Mutant AML
2026-08-12
AG-120 (Ivosidenib) enables a practical workflow for lowering 2-hydroxyglutarate, testing mutant-IDH1 dependency, and linking metabolic inhibition to myeloid differentiation. This guide combines assay design, CD44-informed combination logic, and troubleshooting strategies for reproducible AML research.
-
From PS Biology to Better Capture Workflows
2026-08-12
A translational framework for connecting annexin-V detection of early phosphatidylserine exposure with selective, biotin-enabled magnetic capture—without confusing ex vivo enrichment with in situ measurement.